NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Total Income: ₹2,575.79 lakhs (down 41.5% from ₹4,402.08 lakhs previ | 2026-09-04 |
| Quarterly results · Q1 FY27 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Reporting Period: Q1 ended 30th June 2026 (unaudited financial res | 2026-08-06 |
| Quarterly results · Q4 FY26 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations FY 2026: Rs 2,373.16 lacs (down 45% from Rs 4 | 2026-05-21 |
| Quarterly results · Q3 FY26 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2026 Revenue from Operations: Rs. 727.42 lacs (down 36.6% YoY fr | 2026-02-09 |
| Quarterly results · Q2 FY26 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2026 Revenue from Operations: Rs. 416.74 lacs (vs. Rs. 548.09 la | 2025-11-04 |
| Annual report FY2025 KREBS BIOCHEMICALS & INDUSTRIES LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • Total Income FY2024-25: Rs. 4,402.08 Lacs (down from Rs. 5,087.28 Lacs | 2025-08-28 |
| Quarterly results · Q1 FY26 KREBS BIOCHEMICALS & INDUSTRIES LIMITED – Q1 FY2026 DOCUMENT SUMMARY HEADLINE NUMBERS • Document is a Board Meeting outcome notification dated 7th A | 2025-08-07 |
| Quarterly results | 2025-02-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Krebs Biochemicals and Industries Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.